Ivabradine is as effective as metoprolol in the prevention of ventricular arrhythmias in acute non-reperfused myocardial infarction in the rat

Scientific Reports
Mariusz MarciszekMichał Mączewski


Ventricular arrhythmias are a major source of early mortality in acute myocardial infarction (MI) and remain a major therapeutic challenge. Thus we investigated effects of ivabradine, a presumably specific bradycardic agent versus metoprolol, a β-blocker, at doses offering the same heart rate (HR) reduction, on ventricular arrhythmias in the acute non-reperfused MI in the rat. Immediately after MI induction a single dose of ivabradine/ metoprolol was given. ECG was continuously recorded and ventricular arrhythmias were analyzed. After 6 h epicardial monophasic action potentials (MAPs) were recorded and cardiomyocyte Ca2+ handling was assessed. Both ivabradine and metoprolol reduced HR by 17% and arrhythmic mortality (14% and 19%, respectively, versus 33% in MI, p < 0.05) and ventricular arrhythmias in post-MI rats. Both drugs reduced QTc prolongation and decreased sensitivity of ryanodine receptors in isolated cardiomyocytes, but otherwise had no effect on Ca2+ handling, velocity of conduction or repolarization. We did not find any effects of potential IKr inhibition by ivabradine in this setting. Thus Ivabradine is an equally effective antiarrhythmic agent as metoprolol in early MI in the rat. It could be potentially tested as...Continue Reading


Feb 25, 2003·Journal of the American College of Cardiology·Vincent ProbstHervé Le Marec
Mar 17, 2005·Cardiovascular Research·Naama Zeevi-LevinOfer Binah
May 24, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Hiroshi AshikagaElliot R McVeigh
Mar 24, 2006·Nature·Michael C Sanguinetti, Martin Tristani-Firouzi
Dec 6, 2007·Drugs·Dario DiFrancesco, Jeffrey S Borer
Apr 15, 2008·Progress in Biophysics and Molecular Biology·T G McNaryF B Sachse
Nov 27, 2008·Journal of Cardiovascular Pharmacology·Fanny VaillantPhilippe Chevalier
Jan 7, 2010·Journal of Molecular and Cellular Cardiology·Urszula MackiewiczBohdan Lewartowski
Jun 18, 2010·European Journal of Pharmacology·Jana Kmecova, Jan Klimas
Jul 28, 2010·Journal of Molecular and Cellular Cardiology·Arthur A M WildeCharles Antzelevitch
Mar 5, 2014·Journal of Cellular Physiology·Urszula MackiewiczMichał Mączewski
Oct 24, 2014·Annual Review of Physiology·Zhilin Qu, James N Weiss
Jan 6, 2015·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Jayaprakash ShentharChollenhalli Nanjappa Manjunath
Apr 26, 2015·Journal of the American Heart Association·Dario MelgariJules C Hancox
May 20, 2015·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Yao-Dong LiBao-Peng Tang
Jun 21, 2015·Journal of Molecular and Cellular Cardiology·Katherine M HolzemIgor R Efimov
May 27, 2016·Cardiovascular Research·Michael FriskWilliam E Louch
Aug 9, 2017·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Shawn M LamotheShetuan Zhang
Sep 22, 2018·Cardiovascular Toxicology·Gerrit FrommeyerLars Eckardt
Mar 22, 2019·Nature Reviews. Cardiology·Sebastian ClaussStefan Kääb

Related Concepts

Adrenergic beta-Antagonists
Anti-Arrhythmia Agents
Cardiac Arrhythmia
Heart Rate
Myocardial Infarction
Ventricular Arrhythmia
Acute Myocardial Infarction
Myocytes, Cardiac

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Related Papers

Pacing and Clinical Electrophysiology : PACE
Kadir Uğur MertGurbet Özge Mert
Perspective infirmière : revue officielle de l'Ordre des infirmières et infirmiers du Québec
Guy Sabourin
International Journal of Cardiology
Gökhan ErgünMurat Biteker
© 2021 Meta ULC. All rights reserved